However, a great deal of research has shown that expression of PD-L1 on the membranes of cancer cells is not an indicator of the clinical outcomes of immunotherapy for ccRCC patients [10], which poses uncertainty regarding when or which immunotherapy drugs should be used. The gene discussed is CD274; the disease is nonpapillary renal cell carcinoma.